Andrew Chi, MD, PhD at NYU Langone Medical Center explains how ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine Receptor D2 Antagonist. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.
ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine Receptor D2 AntagonistÂ
